- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Mycophenolate Mofetil
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 269
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Sclerosis (SSc)
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
- Conditions
- Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Anifrolumab
- Combination Product · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 80 Years
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 18 more
- Conditions
- Raynaud, Scleroderma
- Interventions
- Fasudil
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Scleroderma, Calcinosis
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Belumosudil (KD025), Placebo
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more
- Conditions
- Scleroderma
- Interventions
- Not listed
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Interventions
- MQX-503
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Renton, Washington
- Conditions
- Interstitial Lung Disease
- Interventions
- efzofitimod 450 mg, efzofitimod 270 mg, Placebo
- Drug
- Lead sponsor
- aTyr Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • Miami, Florida + 10 more
- Conditions
- Symmetric Limited Morphea
- Interventions
- Medium Dose UVA-1, High Dose UVA-1
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
- Interventions
- German manufactured UVA1 emitting light system
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Systemic Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
- Interventions
- depot leuprolide acetate 3.75 mg, Placebo
- Drug
- Lead sponsor
- Joseph Mccune
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Columbus, Ohio
- Conditions
- Raynaud's Disease, Peripheral Vascular Disease
- Interventions
- PF-00489791
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 23
- States / cities
- Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more
- Conditions
- Systemic Scleroderma
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Plerixafor, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 12
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 5 more
- Conditions
- Interstitial Lung Disease Due to Systemic Disease, Scleroderma
- Interventions
- Amlitelimab, BI 1015550 (Nerandomilast), Placebo
- Drug
- Lead sponsor
- Scleroderma Research Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
- Conditions
- Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
- Interventions
- Ixazomib
- Drug
- Lead sponsor
- Michael M. Pham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Systemic Sclerosis-Associated PAH
- Interventions
- Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
- Biological · Other · Diagnostic Test + 1 more
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 17
- States / cities
- Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- TEPEZZA, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
- Conditions
- SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- CTX112
- Biological
- Lead sponsor
- CRISPR Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 9
- States / cities
- La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more
- Conditions
- Constipation, Bloating
- Interventions
- PRIM-DJ2727, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Sclerosis (SSc), Dermatomyositis, Mixed Connective Tissue Disease (MCTD), Calcinosis
- Interventions
- Sodium Thiosulfate (STS)
- Drug
- Lead sponsor
- Robyn T. Domsic, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
- Interventions
- zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin